This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Nemaline myopathy (rod myopathy)Nemaline Myopathy (Rod Myopathy)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: G71.2 | Special Copayment Reduction: V012 | Coverage period: 5 years
B. SynonymsRod Myopathy, Nemaline Rod Myopathy, congenital rod disease
C. Adult onsetPossible first onset in adulthood — a separate adult-onset form (adult-onset NM) exists; sporadic adult forms other than ACTA1/NEB may be accompanied by hematologic abnormalities (gammopathy)
1. History→ Go to section | First described by Shy et al. in 1963
2. Causes→ Go to section | Mutations in 14 or more sarcomeric protein genes; accumulation of Z-line-derived rods
3. Genetics→ Go to section | NEB (AR), ACTA1 (AD/AR), TPM2/TPM3 (AD), various
4. Epidemiology→ Go to section | Prevalence about 1–2/100,000 births
5. Pathophysiology→ Go to section | Sarcomeric Z-line protein abnormality → rod formation → impaired muscle contraction
6. Symptoms→ Go to section | Varies by form; severe infantile to mild childhood to adult forms
7. Signs→ Go to section | Facial weakness, high-arched palate, scoliosis, respiratory muscle weakness
8. Screening→ Go to section | CK normal to mildly elevated, EMG, muscle MRI
9. Diagnosis→ Go to section | Muscle biopsy (Gomori stain), gene panel
10. Treatment→ Go to section | Supportive care, respiratory and nutritional management; preclinical gene therapy
11. Prognosis→ Go to section | Varies by form; high mortality in the severe infantile form
12. Prevention→ Go to section | Genetic counseling, prenatal genetic diagnosis
13. References→ Go to section | 10 key references

1. Historical background

Nemaline myopathy (NM) was first described as an independent disease in 1963 by Shy, Engel, Somers, Wanko, and colleagues. At the same time, Conen, Murphy, and Donohue also reported similar cases. Initially, the name 'nemaline' was given after the Greek 'nema (thread)', from the peculiar rod- or thread-shaped structures found within muscle fibers.

From 1965 onward, electron microscopic analysis revealed that these nemaline rods are composed of sarcomeric Z-line material. In 1995 Laing et al. identified TPM3 gene mutations as the first genetic cause of NM, and in 1999 Pelin et al. identified NEB (nebulin) gene mutations as the cause of most cases. In 2000 Nowak et al. showed that ACTA1 (alpha-actin 1) mutations are associated with severe NM.

Subsequently, with advances in molecular genetics, 14 or more causative genes have been discovered to date, including TPM2, TNNT1, CFL2, KBTBD13, KLHL40, KLHL41, LMOD3, MYPN, MYO18B, and ADSSL1. Since the 2010s, the introduction of whole-exome sequencing (WES) and muscle panel testing has refined genetic classification, and 'NM without rods', showing a clinical phenotype similar to NM without histologically typical rods, has also been described. Preclinical and small clinical studies of AAV-mediated gene therapy are currently under way.

2. Causes

The cause of NM is structural and functional abnormality due to mutations in genes encoding sarcomere proteins, particularly Z-disc-associated proteins. The two most common causative genes are as follows.

Other causative genes include TPM2 (tropomyosin-β, 9p13), TPM3 (tropomyosin-α1, 1q21), TNNT1 (troponin T1, 19q13), CFL2 (cofilin-2, 14q13), KBTBD13 (19p13), KLHL40 (3p22), KLHL41 (2q31), LMOD3 (3p14), MYPN (10q21), MYO18B (22q11), and ADSSL1 (14q32). The common pathway of rod formation is aggregation of Z-line proteins or thin filament dysfunction.

3. Genetics

The mode of inheritance of NM varies with the causative gene. NEB variants are autosomal recessive (AR); ACTA1 variants are mainly autosomal dominant (AD) due to de novo mutations, but some are AR; TPM2 and TPM3 variants are mostly AD (recessive is rare); and TNNT1 variants are AR.

GeneChromosomeMode of inheritanceFrequencyClinical features
NEB2q22AR~35%Typical childhood form, variable severity
ACTA11q42AD(de novo)/AR~25%Mostly severe infantile form; some mild
TPM29p13AD~4%Mild to moderate; with joint contractures
TPM31q21AD/AR~3%Mild to moderate
TNNT119q13AR~2%Amish NM; severe progression
Others (KLHL40, etc.)VariableMainly AR~10%Severe fetal to infantile form

The NEB gene, consisting of 183 exons, is one of the largest genes in the human genome; sequencing analysis is technically difficult and it contains a complex triplicate repeat region. Standard NGS panels alone may miss all NEB variants, so long-read sequencing or specialized analysis may be needed.

4. General epidemiology

The prevalence of NM is estimated at about 1–2/100,000 births, making it one of the most common forms of congenital myopathy. Founder effects have traditionally been reported in certain ethnic groups. TNNT1 mutations are clustered in the Amish community in the United States. High frequencies of specific variants have also been confirmed in Finland, Israel, and elsewhere.

Sex differences are not marked, and the severe infantile form caused by de novo ACTA1 mutations is evenly distributed worldwide. In Korea as well, the diagnosis rate has been increasing since NGS panels became widespread, with reports mainly of NEB and ACTA1 variants. Diagnostic delay is common in mild forms, so the actual prevalence may be underestimated.

By clinical form, the typical congenital form is the most common (~45%), followed by the severe infantile form (~16%), mild form (~13%), intermediate infantile form (~20%), adult-onset form (~4%), and other forms.

5. Pathophysiology

The core of the pathophysiology of NM is impaired muscle contraction due to qualitative and quantitative abnormalities of the proteins composing the sarcomere thin filament, and aggregation of abnormal proteins into Z-line-derived nemaline rods.

Normally the thin filament is composed of actin, tropomyosin, the troponin complex, nebulin, and others. Nebulin is arranged along the full length of the thin filament and is essential for determining thin filament length and structural stabilization. Nebulin abnormalities cause shortening and destabilization of the thin filament, resulting in reduced muscle contractile force.

Alpha-actin (ACTA1) mutations directly alter the physicochemical structure of the thin filament or interfere with binding to tropomyosin, causing failure of calcium-dependent regulation. Tropomyosin (TPM2, TPM3) mutations cause abnormal thin filament activation responses on calcium binding. As a result, muscle fibers have reduced contractile force, and rods, which are aggregates of abnormal protein, accumulate within the cell.

Rods may form mainly in the cytoplasm, around the nucleus, or even within the nucleus (intranuclear rods — characteristic of ACTA1 variants). On electron microscopy, rods typically show the same lattice structure as the Z-line and contain alpha-actinin, α-actin, nebulin, and others.

6. Symptoms

NM is classified into the following spectrum of 6 clinical phenotypes (Wallgren-Pettersson classification, 2004).

Severe Neonatal Form

Severe respiratory failure at or shortly after birth (requiring mechanical ventilation), generalized hypotonia, absence of movement, loss of oropharyngeal function. Death possible within hours to days without mechanical ventilation. Frequent with ACTA1 de novo mutations and KLHL40 variants.

Moderate Typical/Intermediate Form

Hypotonia in the neonatal period to infancy, variable respiratory difficulty, most eventually achieve walking. Common with NEB variants.

Typical Congenital Form

Neonatal hypotonia, proximal and facial muscle weakness; delayed motor development; most can walk independently; respiratory problems mild to absent.

Mild / Adult-Onset Form

Appears in late childhood or adulthood. No respiratory support needed. In adult NM, there are cases of acquired NM accompanied by monoclonal gammopathy (paraproteinemia), so differentiation is needed.

Atypical/Amish form

TNNT1 variants: progressive rigid myopathy from birth to infancy, diaphragmatic deformity, early death.

7. Signs

8. Screening

TestFindings and significance
Serum CKNormal to mildly elevated (2–3×ULN). A normal CK does not exclude NM.
EMGMyopathic findings. Spontaneous potentials rare.
Muscle MRISelective fatty infiltration of thigh and calf muscles; relatively uniform involvement pattern with NEB variants.
Pulmonary function testsMeasurement of FVC, MIP, MEP; nocturnal SaO₂ monitoring. Assessment of the extent of respiratory muscle involvement.
ECG · echocardiographyBaseline assessment of myocardial involvement (rare, but possible with ACTA1 variants).
Swallowing assessmentVideofluoroscopic swallowing study (VFSS); assessment of aspiration risk.

9. Diagnosis

Muscle biopsy

On modified Gomori trichrome (MGT) staining, rods stain red and are observed in the muscle fibers. Electron microscopy (EM) confirms rods with a Z-line lattice structure. Type 1 fiber predominance and type 2 fiber hypoplasia are commonly accompanying. Intranuclear rods strongly suggest an ACTA1 variant.

Genetic testing

10. Treatment

There is currently no etiologic treatment for NM, and treatment focuses on a multidisciplinary supportive approach.

Respiratory management (top priority)

Nutritional and oropharyngeal management

Rehabilitation therapy

Orthopedic treatment

Treatments under investigation

11. Prognosis

Prognosis varies greatly with clinical form and gene variant.

Progression of scoliosis and respiratory failure are the main prognostic determinants, and respiratory monitoring and early intervention are important. When cardiomyopathy is present, heart failure management is carried out as well.

12. Prevention

13. References

  1. Shy GM, et al. Nemaline myopathy. A new congenital myopathy. Brain. 1963;86:793–810. PMID: 14090428
  2. Wallgren-Pettersson C, et al. Nemaline myopathies. Semin Pediatr Neurol. 2011;18(4):230–236. PMID: 22172422
  3. Pelin K, et al. Mutations in the nebulin gene associated with autosomal recessive nemaline myopathy. Proc Natl Acad Sci USA. 1999;96(5):2305–2310. PMID: 10051637
  4. Nowak KJ, et al. Mutations in the skeletal muscle alpha-actin gene in patients with actin myopathy and nemaline myopathy. Nat Genet. 1999;23(2):208–212. PMID: 10508519
  5. Laing NG, et al. A mutation in the alpha tropomyosin gene TPM3 associated with autosomal dominant nemaline myopathy. Nat Genet. 1995;9(1):75–79. PMID: 7704030
  6. Maggi L, et al. Nemaline myopathies: a current view. J Muscle Res Cell Motil. 2019;40(2):111–126. PMID: 31392591
  7. Ravenscroft G, et al. Mutations in KLHL40 are a frequent cause of severe autosomal-recessive nemaline myopathy. Am J Hum Genet. 2013;93(1):6–18. PMID: 23746549
  8. Colombo I, et al. Early clinical and pre-clinical therapy development in Nemaline myopathy. Expert Opin Ther Targets. 2022;26(12):1011–1021. PMID: 36484417
  9. Yuen M, et al. Leiomodin-3 dysfunction results in thin filament disorganization and nemaline myopathy. J Clin Invest. 2014;124(11):4693–4708. PMID: 25250574
  10. North KN, et al. Nemaline myopathy: current concepts. J Child Neurol. 1997;12(5):333–342. PMID: 9257630